Company / FCF Margin
Axsome Therapeutics, Inc. FCF Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-14.7%
FY2025
5-year range
-53.8% / -14.7%
FY2023-FY2025
Trend
+55.9%
vs FY2024
Sector context
#71 of 134
Health Care
What the data says
At -14.7%, Axsome Therapeutics, Inc.'s fcf margin ranks #71 of 134 in the Health Care sector. Improved from -53.8% to -14.7% over the past 2 years.
Based on SEC 10-K filings.
-14.7% in FY2025.
Improved from -53.8% to -14.7% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#71 of 134 in Health CareTop 53% of 134This company -14.7% Sector average -637.8%
▼
+97.7% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 55.9% year-over-year.
- Currently 623.1pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -14.7% | +55.9% |
| FY2024 | -33.4% | +38.0% |
| FY2023 | -53.8% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026